113 related articles for article (PubMed ID: 9796987)
41. Leucovorin modulation of fluorouracil.
Grogan L; Sotos GA; Allegra CJ
Oncology (Williston Park); 1993 Aug; 7(8):63-72; discussion 75-6. PubMed ID: 8398636
[TBL] [Abstract][Full Text] [Related]
42. Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data.
Chéradame S; Etienne MC; Chazal M; Guillot T; Fischel JL; Formento P; Milano G
Eur J Cancer; 1997 May; 33(6):950-9. PubMed ID: 9291820
[TBL] [Abstract][Full Text] [Related]
43. Azidothymidine in combination with 5-fluorouracil in human colorectal cell lines: in vitro synergistic cytotoxicity and DNA-induced strand-breaks.
Andreuccetti M; Allegrini G; Antonuzzo A; Malvaldi G; Conte PF; Danesi R; Del Tacca M; Falcone A
Eur J Cancer; 1996 Jun; 32A(7):1219-26. PubMed ID: 8758257
[TBL] [Abstract][Full Text] [Related]
44. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil, in CCRF-CEM cells.
Romanini A; Li WW; Colofiore JR; Bertino JR
J Natl Cancer Inst; 1992 Jul; 84(13):1033-8. PubMed ID: 1376779
[TBL] [Abstract][Full Text] [Related]
45. Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor.
Fischel JL; Formento P; Etienne MC; Spector T; Renée N; Milano G
Biochem Pharmacol; 1997 Jun; 53(11):1703-9. PubMed ID: 9264323
[TBL] [Abstract][Full Text] [Related]
46. Sequence-dependent cytotoxic effects of the combination of a new nitrosourea, fotemustine, with 5-fluorouracil plus folinic acid.
Fischel JL; Formento P; Berlion M; Berille J; Gioanni J; Bizzari JP; Milano G
Cancer Chemother Pharmacol; 1991; 28(6):448-54. PubMed ID: 1657424
[TBL] [Abstract][Full Text] [Related]
47. [The potentiation of toxic effects by the combined administration of 5-fluorouracil and folinic acid salts].
Strahlenther Onkol; 1994 Oct; 170(10):616. PubMed ID: 7974177
[No Abstract] [Full Text] [Related]
48. Importance of the irradiation timing within a chemoradiotherapy sequence including cisplatin and 5-FU-folinic acid. Experimental results.
Lagrange JL; Fischel JL; Galliani S; Formento P; Guillot T; Bardon M; Milano G
Eur J Cancer; 1993; 29A(11):1531-5. PubMed ID: 8217357
[TBL] [Abstract][Full Text] [Related]
49. Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment.
Zoetemelk M; Ramzy GM; Rausch M; Nowak-Sliwinska P
Molecules; 2020 Jun; 25(11):. PubMed ID: 32512790
[TBL] [Abstract][Full Text] [Related]
50. Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines.
Harstrick A; Vanhoefer U; Heidemann A; Druyen H; Wilke H; Seeber S
Anticancer Drugs; 1997 Apr; 8(4):391-5. PubMed ID: 9180394
[TBL] [Abstract][Full Text] [Related]
51. Schedule-dependent interaction between raltitrexed and 5-fluorouracil in human colon cancer cell lines in vitro.
Kano Y; Akutsu M; Suzuki K; Yazawa Y; Tsunoda S; Furukawa Y
Oncol Res; 2000; 12(3):137-48. PubMed ID: 11216672
[TBL] [Abstract][Full Text] [Related]
52. [The Molecular Aspect of the Antitumor Effect of Oxaliplatin in Combination with 5-FU].
Kitao H; Kiyonari S; Iimori M; Niimi S; Kataoka Y; Akiyama S; Edahiro K; Nakanishi R; Tokunaga E; Saeki H; Oki E; Kanaji S; Kakeji Y; Maehara Y
Gan To Kagaku Ryoho; 2016 Jun; 43(6):707-14. PubMed ID: 27306806
[TBL] [Abstract][Full Text] [Related]
53. Antitumor Activity of Oxaliplatin, 5-FU and Paclitaxel Given Alone or in Combination with ZD1839 in Human Gastric Carcinoma Cells in vitro.
Jang JH; Lee SH; Kang JH; Sun HS; Nishio K; Saijo N; Kuh HJ
Cancer Res Treat; 2002 Oct; 34(5):372-81. PubMed ID: 26680890
[TBL] [Abstract][Full Text] [Related]
54. Human pharmacokinetic study of heated intraperitoneal oxaliplatin in increasingly hypotonic solutions after complete resection of peritoneal carcinomatosis.
Elias D; El Otmany A; Bonnay M; Paci A; Ducreux M; Antoun S; Lasser P; Laurent S; Bourget P
Oncology; 2002; 63(4):346-52. PubMed ID: 12417789
[TBL] [Abstract][Full Text] [Related]
55. Heterogeneity in cancer cells: variation in drug response in different primary and secondary colorectal cancer cell lines in vitro.
Arul M; Roslani AC; Cheah SH
In Vitro Cell Dev Biol Anim; 2017 May; 53(5):435-447. PubMed ID: 28120247
[TBL] [Abstract][Full Text] [Related]
56. Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy.
Prete SP; Turriziani M; Massara MC; De Rossi A; Correale P; De Vecchis L; Torino F; Bonmassar L; Aquino A
J Exp Clin Cancer Res; 2008 May; 27(1):5. PubMed ID: 18577244
[TBL] [Abstract][Full Text] [Related]
57. Biomodulation of 5-Fu cytotoxicity by folinic acid and its stereoisomers: in vitro experiments with different cell lines of prostatic cancer.
Breul J; Jakse G; Hartung R
Urol Res; 1995; 23(3):163-7. PubMed ID: 7483142
[TBL] [Abstract][Full Text] [Related]
58. Salidroside could enhance the cytotoxic effect of L‑OHP on colorectal cancer cells.
Shi X; Zhao W; Yang Y; Wu S; Lv B
Mol Med Rep; 2018 Jan; 17(1):51-58. PubMed ID: 29115408
[TBL] [Abstract][Full Text] [Related]
59. Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation.
Pangeni R; Choi SW; Jeon OC; Byun Y; Park JW
Int J Nanomedicine; 2016; 11():6379-6399. PubMed ID: 27942212
[TBL] [Abstract][Full Text] [Related]
60. Long-term stability of 5-fluorouracil and folinic acid admixtures.
Milano G; Etienne MC; Cassuto-Viguier E; Renée N; Bousselet M; Guillot T; Lecompte D
Eur J Cancer; 1992; 29A(1):129-32. PubMed ID: 1445730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
